Protective effect of the acyclic nucleoside phosphonate tenofovir toward human T-cell leukemia/lymphotropic virus type 1 infection of human peripheral blood mononuclear cells in vitro

Antiviral Research

Volumn 68, Issue 3, 2005, Pages 154-162

  Balestrieri, Emanuela ^a   Sciortino, Maria Teresa ^b   Mastino, Antonio ^b   Macchi, Beatrice ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Acyclic nucleoside phosphonates; HTLV 1; Reverse transcriptase; Reverse transcriptase inhibitors; Tenofovir

Indexed keywords

ACYCLIC NUCLEOSIDE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS DNA; VIRUS ENZYME; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FREE SYSTEM; CELL GROWTH; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IRRADIATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CULTURE; VIRUS GENE; VIRUS PARTICLE;

ADENINE; ANTI-HIV AGENTS; DNA, VIRAL; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA, T-CELL; LEUKOCYTES, MONONUCLEAR; PHOSPHONIC ACIDS;

DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 27744559848     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2005.09.001     Document Type: Article

References (35)

1. E. Balestrieri, G. Forte, C. Matteucci, A. Mastino, and B. Macchi Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro Antimicrob. Agents Chemother. 46 2002 3080 3083
2. J. Balzarini, and E. De Clercq Acyclic purine nucleoside phosphonates as retrovirus inhibitors D.J. Jeffries E. De Clercq Antiviral Chemotherapy 1995 John Wiley and Sons Chichester, Sussex 41 79
3. J. Balzarini, S. Aquaro, C.F. Perno, M. Witvrouw, A. Holy, and E. De Clercq Activity of (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems Biochem. Biophys. Res. Commun. 219 1996 337 341
4. C.R. Bangham Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control Int. J. Hematol. 78 2003 297 303
5. G. Biesecker, S. Karimi, S.J. Desjardins, D. Meyer, B. Abbot, R. Bendele, and F. Richardson Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks Antiviral Res. 58 2003 217 225
6. G. Birkus, M. Hajek, P. Kramata, I. Votruba, A. Holý, and B. Otova Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases α, δ and ε Antimicrob. Agents Chemother. 46 2002 1610 1613
7. G. Birkus, M.J. Hitchcock, and T. Cihlar Assessment of mitochondrial toxicity in human cells treated with Tenofovir: comparison with other nucleoside reverse transcriptase inhibitors Antimicrob. Agents Chemother 46 2002 716 723
8. T. Chapman, J. McGavin, and S. Noble Tenofovir disoproxil fumarate Drugs 63 2003 1597 1608
9. U. Chiacchio, E. Balestrieri, B. Macchi, D. Iannazzo, A. Piperno, A. Rescifina, R. Romeo, M. Saglimbeni, M.T. Sciortino, V. Valveri, A. Mastino, and G. Romeo Synthesis of phosphonated carbocyclic-2′-oxa-3′-aza- nucleosides: novel inhibitors of reverse transcriptase J. Med. Chem. 48 2004 1389 1394
10. T. Cihlar, G. Birkus, D.E. Greenwalt, and M.J. Hitchcock Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors Antiviral Res. 54 2002 37 45
11. C. Creput, G. Gonzalez-Canali, G. Hill, C. Piketty, M. Kazatchkine, and D. Nochy Renal lesions in HIV-1 positive patient treated with tenofovir AIDS 17 2003 935 937
12. E. De Clercq Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir in treatment of DNA virus and retrovirus infections Clin. Microbiol. Rev. 16 2003 569 596
13. S.G. Deeks, P. Barditch-Crovo, P.S. Lietman, F. Hwang, K.C. Cundy, J.F. Rooney, N.S. Hellmann, S. Safrin, and J.O. Kahn Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults Antimicrob. Agents Chemother. 42 1998 2380 2384
14. R.F. Edlich, J.A. Arnette, and F.M. Williams Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I) J. Emerg. Med. 18 2000 109 119
15. J.G. Garcia-Lerma, S. Nidtha, and W. Heneine Susceptibility of human T cell leukemia virus type 1 to reverse transcriptase inhibitors: evidence for resistance to lamivudine J. Infect. Dis. 184 2001 507 510
16. P.S. Gill, W. Harrington Jr., M.H. Kaplan, R.C. Ribeiro, J.M. Bennett, H.A. Liebman, M. Berstein-Singer, B.M. Espina, L. Cabral, S. Allen, S. Kornblau, M.C. Pike, and A.M. Levine Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine N. Engl. J. Med. 332 1995 1744 1748
17. R.A. Heijtink, J. Kruining, G.A. de Wilde, J. Balzarini, E. De Clercq, and S.W. Schalm Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture Antimicrob. Agents Chemother. 38 1994 2180 2182
18. S.A. Hill, P.A. Lloyd, S. McDonald, J. Wykoff, and D. Derse Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors J. Infect. Dis. 188 2003 424 427
19. T. Igakura, J.C. Stinchcombe, P.K.C. Goon, G.P. Taylor, J.N. Weber, G.M. Griffiths, Y. Tanaka, M. Osame, and C.R. Bangham Spread of HTLV-1 between lymphocytes by virus-induced polarization of the cytoskeleton Science 299 2003 1713 1716
20. T. Kinoshita, M. Shimoyama, K. Tobinai, M. Ito, S. Ito, S. Ikeda, K. Tajima, K. Shimotohno, and T. Sugimura Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction Proc. Natl. Acad. Sci. U.S.A. 86 1989 5620 5624
21. H. Lee, J. Hanes, and K.A. Johnson Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase Biochemistry 42 2003 14711 14719
22. B. Macchi, I. Faraoni, J. Zhang, S. Grelli, C. Favalli, A. Mastino, and E. Bonmassar AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro J. Gen. Virol. 78 1997 1007 1016
23. A. Machuca, and V. Soriano In vivo fluctuation of HTLV-1 and HTLV-1I proviral load in patients receiving antiretroviral drugs J. Acquir. Immune Defic. Syndr. 24 2000 189 193
24. S. Matsushita, H. Mitsuya, M.S. Reitz, and S. Broder Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I J. Clin. Invest. 80 1987 394 400
25. C. Matteucci, E. Balestrieri, B. Macchi, and A. Mastino Modulation of apoptosis during HTLV-1-mediated immortalization process in vitro J. Med. Virol. 74 2004 473 483
26. M.A. Medici, M.T. Sciortino, D. Perri, C. Amici, E. Avitabile, M. Ciotti, E. Balestrieri, E. De Smaele, G. Franzoso, and A. Mastino Protection by herpes simplex virus glycoprotein D against Fas-mediated apoptosis: role of nuclear factor kappa-B J. Biol. Chem. 278 2003 36059 36067
27. I. Miyoshi, I. Kubonishi, S. Yoshimoto, and Y. Shiraishi A T-cell line derived from normal human cord leukocytes by co-culturing with human leukemic T-cells Gann 72 1981 978 981
28. L. Naesens, R. Snoeck, G. Andrei, J. Balzarini, J. Neyts, and E. De Clercq HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections Antiviral Chem. Chemother. 8 1997 1 23
29. G. Palù, S. Stefanelli, M. Rassu, C. Parolin, J. Balzarini, and E. De Clercq Cellular uptake of phosphonylmethoxyalkylpurine derivatives Antiviral Res. 16 1991 115 119
30. R.T. Schooley, P. Ruane, R.A. Myers, G. Beall, H. Lampiris, D. Berger, S.S. Chen, M.D. Miller, E. Isaacson, and A.K. Cheng Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized double-blind study AIDS 16 2002 1257 1263
31. P. Silvera, P. Racz, K. Racz, N. Bischofberger, C. Crabbs, J. Yalley-Ogunro, J. Greenhouse, B. Jiang, and M.G. Lewis Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques AIDS Res. Hum. Retroviruses 16 2000 791 800
32. G.P. Taylor, S.E. Hall, S. Navarrete, C.A. Michie, R. Davis, A.D. Witkover, M. Rossor, M.A. Nowak, P. Rudge, E. Matutes, C.R. Bangham, and J.N. Weber Effect of lamivudine on human T-cell leukemia virus type I (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1 associated myelopathy J. Virol. 73 1999 10289 10295
33. C.C. Tsai, K.E. Follis, A. Sabo, T.W. Beck, R.F. Grant, N. Bischofberger, R.E. Benveniste, and R. Black Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine Science 270 1995 1197 1199
34. C.C. Tsai, K.E. Follis, T.W. Beck, A. Sabo, N. Bischofberger, and P.J. Dailey Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques AIDS Res. Hum. Retroviruses 13 1997 707 712
35. K.K. Van Rompay, J.M. Cherrington, M.L. Marthas, C.J. Berardi, A.S. Mulato, A. Spinner, R.P. Tarara, D.R. Canfield, S. Telm, N. Bischofberger, and N.C. Pedersen 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques Antimicrob. Agents Chemother. 40 1997 2586 2591